Novo Reports Strong Q3 Earnings Driven by Wegovy Sales Surge
Written with artificial intelligence.

Novo Nordisk exceeded quarterly earnings expectations, driven by robust sales of its Wegovy pill, which reached 5.4 billion Danish kroner. The company has revised its outlook for revenue and operating profit growth, reflecting a positive shift in its financial trajectory.
Earnings Overview
Novo Nordisk reported a strong third quarter, with sales reaching 79.2 billion Danish kroner ($11.9 billion), marking a 4% increase year-on-year at constant exchange rates. This figure surpassed the FactSet estimate of 73.6 billion kroner. Adjusted operating profit (EBIT) was 31.7 billion kroner, exceeding expectations of 28.6 billion kroner.
Wegovy Sales Surge
Sales of the Wegovy pill, launched earlier this year, significantly outperformed expectations, totaling 5.4 billion kroner compared to analyst forecasts of approximately 4.5 billion kroner. The company noted strong momentum in the U.S. market, maintaining an 80% share despite increasing competition. CEO Mike Doustdar indicated that the company is recovering from previous challenges, particularly in the face of competition from Eli Lilly.
Outlook and Future Plans
Novo has updated its outlook for adjusted revenue and operating profit growth to a range of -2% to 2% at constant exchange rates, improving from a prior forecast of -6% to flat. The company is also preparing to launch CagriSema, a new weight-loss treatment, although analysts remain cautious about its commercial potential due to competition.
Leadership Changes
In a notable management shift, CFO Karsten Munk Knudsen will depart at the end of 2026 after 27 years with the company. He will be succeeded by Luigi La Corte, currently the CFO of Galderma. This leadership change comes as Novo seeks to stabilize its operations and regain market position.
Market Reaction
Following the earnings report, Novo shares rose as much as 6% in early trading, though they are still down about 13% year-to-date. Investors are closely watching the competitive landscape, particularly regarding the performance of next-generation weight-loss drugs from both Novo and Eli Lilly.
